Alcon AG (ALC) Stock Price Today
Aura AI Summary
Key Stats
- $32.03BMarket Cap
- 2,399,449Volume
- HealthSector
- $87.1852W High
- $62.0252W Low
- 70 DaysTypical Hold Time
- $35.87BEnterprise Value
- 0.54%Div Yield
- 0% Sell | 100% BuyTrading Activity
Track Alcon AG (ALC) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Alcon AG has traded between a low of $62.02 and a high of $87.18, highlighting its annual price range. Buy and sell Alcon AG shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Most Recent News
Changan signs European partnerships and launches local service program to boost market presence
At the 2026 Mondial de l’Auto, Changan Automobile signed letters of intent with eight companies across seven European markets and launched its "with U" service program. This marks a strategic move to build a strong local ecosystem combining manufactu...

Changan strengthens European presence with new partnerships and local service launch
Changan Automobile announced new partnerships covering seven European markets and launched its "with U" service program at Mondial de l’Auto 2026. This marks a shift from market entry to building a local ecosystem including manufacturing, sales, serv...

Biotech IPOs and inverse ETFs lead market gains with strong debut and leveraged moves.
Recent biotech IPOs Iambic Therapeutics and City Therapeutics saw significant price jumps, rising 25.9% and 22.2% respectively after their market debuts, raising substantial capital. Inverse leveraged ETFs SMCZ and SMST also gained sharply as their u...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.